{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:11:44Z","timestamp":1774379504786,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intrahepatic cholangiocarcinoma (ICC) features poor survival due to frequent recurrences and limited prognostic markers. Using mass spectrometry-based proteomics, we analyze two independent cohorts comprising 80 and 62 treatment-naive ICC tumors, along with 9 independent patient-derived xenografts (PDX). In the first cohort, we identify two subclusters with distinct times-to-recurrence (TTR): An extracellular matrix (ECM)-enriched cluster (mean TTR 859 days) and a proliferation cluster (mean TTR 229 days). A 4-protein classifier trained on our cohort accurately stratifies these clusters in the Dong et al. dataset (2022) and in our second cohort, revealing similar proteomic motifs and clinical outcomes. The translation regulator EIF4A1, enriched in ICCs of both clusters, emerges as a therapeutic target, as its inhibition with eFT226 significantly reduces tumor growth in an ICC PDX model. Proteomic analyses of various PDX models also emphasize the critical role of tumor-stroma interactions in ICC. Overall, this study establishes two prognostic proteomic clusters, validates their relevance across datasets, and highlights EIF4A1 inhibition as a potential therapeutic strategy.<\/jats:p>","DOI":"10.1038\/s41467-026-70817-1","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:36:17Z","timestamp":1774283777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9978-1761","authenticated-orcid":false,"given":"Tilman","family":"Werner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara-Luisa","family":"Budau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-9670","authenticated-orcid":false,"given":"Annika","family":"Topitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Cosenza-Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-6821","authenticated-orcid":false,"given":"Niko","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-6944","authenticated-orcid":false,"given":"Frank","family":"Hause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"R\u00fchlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannis","family":"Heyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0448-7999","authenticated-orcid":false,"given":"Konrad","family":"Kurowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-7343","authenticated-orcid":false,"given":"Julia","family":"Sch\u00fcler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp Anton","family":"Holzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlie","family":"Sigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura H.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8558-0347","authenticated-orcid":false,"given":"Peter","family":"Bronsert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-7653","authenticated-orcid":false,"given":"Oliver","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"70817_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales, J. M. et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261\u2013280 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"70817_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"70817_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"SI Ilyas","year":"2018","unstructured":"Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95\u2013111 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70817_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan, S. A., Tavolari, S. & Brandi, G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 39, 19\u201331 (2019).","journal-title":"Liver Int."},{"key":"70817_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"D Alvaro","year":"2023","unstructured":"Alvaro, D. et al. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol. 79, 181\u2013208 (2023).","journal-title":"J. Hepatol."},{"key":"70817_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley, R. K., Bridgewater, J., Gores, G. J. & Zhu, A. X. Systemic therapies for intrahepatic cholangiocarcinoma. J. Hepatol. 72, 353\u2013363 (2020).","journal-title":"J. Hepatol."},{"key":"70817_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater, J. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 60, 1268\u20131289 (2014).","journal-title":"J. Hepatol."},{"key":"70817_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros, M. N., Economopoulos, K. P., Alexiou, V. G. & Pawlik, T. M. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 149, 565 (2014).","journal-title":"JAMA Surg."},{"key":"70817_CR9","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1245\/s10434-019-07353-4","volume":"26","author":"L-S Hu","year":"2019","unstructured":"Hu, L.-S. et al. Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 26, 2549\u20132557 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"70817_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline, J. et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J. Clin. Oncol. 37, 658\u2013667 (2019).","journal-title":"J. Clin. Oncol."},{"key":"70817_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata, T. et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br. J. Surg. 105, 192\u2013202 (2018).","journal-title":"Br. J. Surg."},{"key":"70817_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose, J. N. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20, 663\u2013673 (2019).","journal-title":"Lancet Oncol."},{"key":"70817_CR13","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1245\/s10434-021-09671-y","volume":"28","author":"ZV Fong","year":"2021","unstructured":"Fong, Z. V., Brownlee, S. A., Qadan, M. & Tanabe, K. K. The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines. Ann. Surg. Oncol. 28, 2660\u20132674 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"70817_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.hpb.2017.06.008","volume":"19","author":"BN Reames","year":"2017","unstructured":"Reames, B. N. et al. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. HPB 19, 901\u2013909 (2017).","journal-title":"HPB"},{"key":"70817_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi, K. et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401, 195\u2013203 (2023).","journal-title":"Lancet"},{"key":"70817_CR16","unstructured":"Amin, M.B. et al. (eds.) AJCC Cancer Staging Manual (8th edition). Springer https:\/\/link.springer.com\/book\/9783319406176 (2017)."},{"key":"70817_CR17","doi-asserted-by":"crossref","unstructured":"Brierley, J. D., Gospodarowicz, M. K. & Wittekind, C. (eds.) TNM Classification of Malignant Tumours. Wiley-Blackwell (2017).","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"70817_CR18","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.7150\/jca.63008","volume":"13","author":"K-L Budau","year":"2022","unstructured":"Budau, K.-L. et al. Prognostic impact of tumor budding in intrahepatic cholangiocellular carcinoma. J. Cancer 13, 2457\u20132471 (2022).","journal-title":"J. Cancer"},{"key":"70817_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/IJPM.IJPM_578_17","volume":"61","author":"M Vyas","year":"2018","unstructured":"Vyas, M. & Jain, D. A practical diagnostic approach to hepatic masses. Indian J. Pathol. Microbiol. 61, 2 (2018).","journal-title":"Indian J. Pathol. Microbiol."},{"key":"70817_CR20","first-page":"9","volume":"15","author":"C Stroescu","year":"2006","unstructured":"Stroescu, C., Herlea, V., Dragnea, A. & Popescu, I. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J. Gastrointestin. Liver Dis. 15, 9\u201314 (2006).","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"70817_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1309\/59TNEFALUL5WJ94M","volume":"125","author":"J-Y Lei","year":"2006","unstructured":"Lei, J.-Y., Bourne, P. A., diSant\u2019Agnese, P. A. & Huang, J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am. J. Clin. Pathol. 125, 519\u2013525 (2006).","journal-title":"Am. J. Clin. Pathol."},{"key":"70817_CR22","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A. et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin. Cancer Res. 24, 4154\u20134161 (2018).","journal-title":"Clin. Cancer Res."},{"key":"70817_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.31092","volume":"72","author":"S Job","year":"2020","unstructured":"Job, S. et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 72, 965\u2013981 (2020).","journal-title":"Hepatology"},{"key":"70817_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","volume":"72","author":"MA Martin-Serrano","year":"2023","unstructured":"Martin-Serrano, M. A. et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 72, 736\u2013748 (2023).","journal-title":"Gut"},{"key":"70817_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","volume":"32","author":"J Chaisaingmongkol","year":"2017","unstructured":"Chaisaingmongkol, J. et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32, 57\u201370.e3 (2017).","journal-title":"Cancer Cell"},{"key":"70817_CR26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7, 1116\u20131135 (2017).","journal-title":"Cancer Discov"},{"key":"70817_CR27","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ng.2813","volume":"45","author":"Y Jiao","year":"2013","unstructured":"Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470\u20131473 (2013).","journal-title":"Nat. Genet."},{"key":"70817_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong, L. et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 40, 70\u201387.e15 (2022).","journal-title":"Cancer Cell"},{"key":"70817_CR29","doi-asserted-by":"publisher","first-page":"e004892","DOI":"10.1136\/jitc-2022-004892","volume":"10","author":"J Lin","year":"2022","unstructured":"Lin, J. et al. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities. J. Immunother. Cancer 10, e004892 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"70817_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/hep.32624","volume":"77","author":"M Deng","year":"2023","unstructured":"Deng, M. et al. Proteogenomic characterization of cholangiocarcinoma. Hepatology 77, 411\u2013429 (2023).","journal-title":"Hepatology"},{"key":"70817_CR31","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1021\/pr501254j","volume":"14","author":"NJ Edwards","year":"2015","unstructured":"Edwards, N. J. et al. The CPTAC Data Portal: a resource for cancer proteomics research. J. Proteome Res. 14, 2707\u20132713 (2015).","journal-title":"J. Proteome Res."},{"key":"70817_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Beyer, A. & Aebersold, R. On the dependency of cellular protein levels on mRNA abundance. Cell 165, 535\u2013550 (2016).","journal-title":"Cell"},{"key":"70817_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30094-0","volume":"13","author":"K Fr\u00f6hlich","year":"2022","unstructured":"Fr\u00f6hlich, K. et al. Benchmarking of analysis strategies for data-independent acquisition proteomics using a large-scale dataset comprising inter-patient heterogeneity. Nat. Commun. 13, 2622 (2022).","journal-title":"Nat. Commun."},{"key":"70817_CR34","doi-asserted-by":"publisher","unstructured":"Cao, J. et al. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis. Oncol. 557\u2013569 https:\/\/doi.org\/10.1200\/PO.18.00414 (2020).","DOI":"10.1200\/PO.18.00414"},{"key":"70817_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/hbsn.2016.11.04","volume":"6","author":"S Vijgen","year":"2017","unstructured":"Vijgen, S., Terris, B. & Rubbia-Brandt, L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg. Nutr. 6, 22\u201334 (2017).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"70817_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2008.03.025","volume":"49","author":"R Nishino","year":"2008","unstructured":"Nishino, R. et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J. Hepatol. 49, 207\u2013216 (2008).","journal-title":"J. Hepatol."},{"key":"70817_CR37","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1007\/s11010-021-04216-z","volume":"476","author":"S Appunni","year":"2021","unstructured":"Appunni, S. et al. Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance. Mol. Cell. Biochem. 476, 3935\u20133950 (2021).","journal-title":"Mol. Cell. Biochem."},{"key":"70817_CR38","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/bjc.2012.59","volume":"106","author":"K Yamamoto","year":"2012","unstructured":"Yamamoto, K. et al. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br. J. Cancer 106, 1214\u20131223 (2012).","journal-title":"Br. J. Cancer"},{"key":"70817_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V. & Locasale, J. W. The Warburg Effect: How does it benefit cancer cells? Trends Biochem. Sci. 41, 211\u2013218 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"70817_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jclinpath-2020-206927","volume":"74","author":"MA Al Barashdi","year":"2021","unstructured":"Al Barashdi, M. A., Ali, A., McMullin, M. F. & Mills, K. Protein tyrosine phosphatase receptor type C (PTPRC or CD45). J. Clin. Pathol. 74, 548\u2013552 (2021).","journal-title":"J. Clin. Pathol."},{"key":"70817_CR41","doi-asserted-by":"publisher","first-page":"e14349","DOI":"10.1111\/eci.14349","volume":"54","author":"KM Skubitz","year":"2024","unstructured":"Skubitz, K. M. The role of CEACAMs in neutrophil function. Eur. J. Clin. Invest. 54, e14349 (2024).","journal-title":"Eur. J. Clin. Invest."},{"key":"70817_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2169","volume":"7","author":"M Karlsson","year":"2021","unstructured":"Karlsson, M. et al. A single\u2013cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).","journal-title":"Sci. Adv."},{"key":"70817_CR43","unstructured":"The Human Protein Atlas. CD14 Protein Expression Summary, https:\/\/v23.proteinatlas.org\/ENSG00000170458-CD14 (accessed 16 March 2016)."},{"key":"70817_CR44","unstructured":"The Human Protein Atlas. CD163 Protein Expression Summary, https:\/\/v23.proteinatlas.org\/ENSG00000177575-CD163 (accessed 16 March 2016)."},{"key":"70817_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.acthis.2016.05.002","volume":"118","author":"M Jur\u00edkov\u00e1","year":"2016","unstructured":"Jur\u00edkov\u00e1, M., Danihel, \u013d, Pol\u00e1k, \u0160 & Varga, I. Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem 118, 544\u2013552 (2016).","journal-title":"Acta Histochem"},{"key":"70817_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.31083\/j.fbl2804075","volume":"28","author":"KH Ong","year":"2023","unstructured":"Ong, K. H. et al. Prognostic significance of DNA topoisomerase II alpha (TOP2A) in cholangiocarcinoma. Front. Biosci. 28, 75 (2023).","journal-title":"Front. Biosci."},{"key":"70817_CR47","first-page":"2304","volume":"15","author":"P Zheng","year":"2023","unstructured":"Zheng, P. et al. Glucose 6 phosphatase dehydrogenase (G6PD): a novel diagnosis marker related to gastrointestinal cancers. Am. J. Transl. Res. 15, 2304\u20132328 (2023).","journal-title":"Am. J. Transl. Res."},{"key":"70817_CR48","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/0008-5472.CAN-08-0565","volume":"68","author":"N Shivapurkar","year":"2008","unstructured":"Shivapurkar, N. et al. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res. 68, 7448\u20137456 (2008).","journal-title":"Cancer Res."},{"key":"70817_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1097\/MPA.0000000000001871","volume":"50","author":"H Kono","year":"2021","unstructured":"Kono, H. et al. Cytoglobin as a prognostic factor for pancreatic ductal adenocarcinoma: a retrospective analysis of 75 patients. Pancreas 50, 994\u2013999 (2021).","journal-title":"Pancreas"},{"key":"70817_CR50","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20187718","volume":"52","author":"H Cheng","year":"2018","unstructured":"Cheng, H. et al. HtrA1 suppresses the growth of pancreatic cancer cells by modulating Notch-1 expression. Braz. J. Med. Biol. Res. 52, e7718 (2018).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"70817_CR51","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.7150\/ijbs.44429","volume":"16","author":"X Zhao","year":"2020","unstructured":"Zhao, X. et al. Septin4 promotes cell death in human colon cancer cells by interacting with BAX. Int. J. Biol. Sci. 16, 1917\u20131928 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"70817_CR52","doi-asserted-by":"publisher","first-page":"e1734","DOI":"10.1093\/oncolo\/oyae170","volume":"29","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. FGFR2 fusion\/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma. Oncologist 29, e1734\u2013e1747 (2024).","journal-title":"Oncologist"},{"key":"70817_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"70817_CR54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1586\/14789450.2013.841547","volume":"10","author":"H Shahinian","year":"2013","unstructured":"Shahinian, H., Tholen, S. & Schilling, O. Proteomic identification of protease cleavage sites: cell-biological and biomedical applications. Expert Rev. Proteomics 10, 421\u2013433 (2013).","journal-title":"Expert Rev. Proteomics"},{"key":"70817_CR55","doi-asserted-by":"crossref","unstructured":"Cosenza-Contreras, M. et al. TermineR: Extracting information on endogenous proteolytic processing from shotgun proteomics data. Proteomics 24, e2300491 (2024).","DOI":"10.1002\/pmic.202300491"},{"key":"70817_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/proteomes9020026","volume":"9","author":"M Fahrner","year":"2021","unstructured":"Fahrner, M., Kook, L., Fr\u00f6hlich, K., Biniossek, M. L. & Schilling, O. A systematic evaluation of semispecific peptide search parameter enables identification of previously undescribed N-terminal peptides and conserved proteolytic processing in cancer cell lines. Proteomes 9, 26 (2021).","journal-title":"Proteomes"},{"key":"70817_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154604","volume":"132","author":"SA Lim","year":"2022","unstructured":"Lim, S. A. et al. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J. Clin. Invest. 132, e154604 (2022).","journal-title":"J. Clin. Invest."},{"key":"70817_CR58","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov."},{"key":"70817_CR59","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1021\/acs.jproteome.3c00164","volume":"22","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Species-deconvolved proteomics for in situ investigation of tumor-stroma interactions after treatment of pancreatic cancer patient-derived xenografts with combined gemcitabine and paclitaxel. J. Proteome Res. 22, 2436\u20132449 (2023).","journal-title":"J. Proteome Res."},{"key":"70817_CR60","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.bbagrm.2014.09.006","volume":"1849","author":"J Chu","year":"2015","unstructured":"Chu, J. & Pelletier, J. Targeting the eIF4A RNA helicase as an anti-neoplastic approach. Biochim. Biophys. Acta BBA Gene Regul. Mech. 1849, 781\u2013791 (2015).","journal-title":"Biochim. Biophys. Acta BBA Gene Regul. Mech."},{"key":"70817_CR61","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1158\/0008-5472.CAN-20-2929","volume":"81","author":"K Singh","year":"2021","unstructured":"Singh, K. et al. Targeting eIF4A-dependent translation of KRAS signaling molecules. Cancer Res. 81, 2002\u20132014 (2021).","journal-title":"Cancer Res."},{"key":"70817_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02390-0","volume":"21","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC\/miR-9 signaling. Cancer Cell Int. 21, 670 (2021).","journal-title":"Cancer Cell Int."},{"key":"70817_CR63","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3390\/ijms24032055","volume":"24","author":"SM Steinmann","year":"2023","unstructured":"Steinmann, S. M. et al. eIF4A1 is a prognostic marker and actionable target in human hepatocellular carcinoma. Int. J. Mol. Sci. 24, 2055 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"70817_CR64","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.jhepr.2025.101416","volume":"7","author":"W Mi","year":"2025","unstructured":"Mi, W. et al. Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma. JHEP Rep. Innov. Hepatol. 7, 101416 (2025).","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"70817_CR65","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.1021\/acs.jmedchem.0c00182","volume":"63","author":"JT Ernst","year":"2020","unstructured":"Ernst, J. T. et al. Design of development candidate eFT226, a first in class inhibitor of eukaryotic initiation factor 4A RNA helicase. J. Med. Chem. 63, 5879\u20135955 (2020).","journal-title":"J. Med. Chem."},{"key":"70817_CR66","doi-asserted-by":"publisher","first-page":"766298","DOI":"10.3389\/fonc.2021.766298","volume":"11","author":"A Gerson-Gurwitz","year":"2021","unstructured":"Gerson-Gurwitz, A. et al. Zotatifin, an eIF4A-selective inhibitor, blocks tumor growth in receptor tyrosine kinase driven tumors. Front. Oncol. 11, 766298 (2021).","journal-title":"Front. Oncol."},{"key":"70817_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172503","volume":"133","author":"N Zhao","year":"2023","unstructured":"Zhao, N. et al. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J. Clin. Invest. 133, e172503 (2023).","journal-title":"J. Clin. Invest."},{"key":"70817_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12014-018-9188-y","volume":"15","author":"MC F\u00f6ll","year":"2018","unstructured":"F\u00f6ll, M. C. et al. Reproducible proteomics sample preparation for single FFPE tissue slices using acid-labile surfactant and direct trypsinization. Clin. Proteomics 15, 11 (2018).","journal-title":"Clin. Proteomics"},{"key":"70817_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100871","volume":"36","author":"J Werner","year":"2023","unstructured":"Werner, J. et al. Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling. Neoplasia 36, 100871 (2023).","journal-title":"Neoplasia"},{"key":"70817_CR70","doi-asserted-by":"publisher","unstructured":"Werner, T. Proteomic characterization of intrahepatic cholangiocarcinoma identifies prognostic subgroups and EIF4A1 as therapeutic target. Zenodo https:\/\/doi.org\/10.5281\/ZENODO.18302883 (2026).","DOI":"10.5281\/ZENODO.18302883"},{"key":"70817_CR71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12014-026-09582-8","volume":"23","author":"A Topitsch","year":"2026","unstructured":"Topitsch, A. et al. ProteoBoostR: an interactive framework for supervised machine learning in clinical proteomics. Clin. Proteomics 23, 4 (2026).","journal-title":"Clin. Proteomics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70817-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70817-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70817-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:01:55Z","timestamp":1774368115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70817-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70817"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70817-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.S., P.B., T.W., K.B., and M.C.C. have filed a patent application on ICC risk-stratifying protein markers. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2741"}}